Vijaya Diagnostic Centre Limited (VIJAYA) - Net Assets
Based on the latest financial reports, Vijaya Diagnostic Centre Limited (VIJAYA) has net assets worth Rs9.57 Billion INR (≈ $103.51 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs15.07 Billion ≈ $162.98 Million USD) and total liabilities (Rs5.50 Billion ≈ $59.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Vijaya Diagnostic Centre Limited (VIJAYA) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs9.57 Billion |
| % of Total Assets | 63.51% |
| Annual Growth Rate | 24.45% |
| 5-Year Change | 103.85% |
| 10-Year Change | N/A |
| Growth Volatility | 6.07 |
Vijaya Diagnostic Centre Limited - Net Assets Trend (2019–2026)
This chart illustrates how Vijaya Diagnostic Centre Limited's net assets have evolved over time, based on quarterly financial data. See Vijaya Diagnostic Centre Limited defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Vijaya Diagnostic Centre Limited (2019–2026)
The table below shows the annual net assets of Vijaya Diagnostic Centre Limited from 2019 to 2026. For live valuation and market cap data, see Vijaya Diagnostic Centre Limited (VIJAYA) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs9.57 Billion ≈ $103.51 Million |
+19.77% |
| 2025-03-31 | Rs7.99 Billion ≈ $86.42 Million |
+21.10% |
| 2024-03-31 | Rs6.60 Billion ≈ $71.37 Million |
+20.72% |
| 2023-03-31 | Rs5.47 Billion ≈ $59.12 Million |
+16.42% |
| 2022-03-31 | Rs4.70 Billion ≈ $50.78 Million |
+30.71% |
| 2021-03-31 | Rs3.59 Billion ≈ $38.85 Million |
+31.04% |
| 2020-03-31 | Rs2.74 Billion ≈ $29.65 Million |
+32.43% |
| 2019-03-31 | Rs2.07 Billion ≈ $22.39 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Vijaya Diagnostic Centre Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs102.90 Million | 1.08% |
| Other Components | Rs9.47 Billion | 98.92% |
| Total Equity | Rs9.57 Billion | 100.00% |
Vijaya Diagnostic Centre Limited Competitors by Market Cap
The table below lists competitors of Vijaya Diagnostic Centre Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Laibao High-Technology Co Ltd
SHE:002106
|
$1.45 Billion |
|
Hefei Jianghang Aircraft Equipment Corporation Ltd
SHG:688586
|
$1.45 Billion |
|
Kosmos Energy Ltd
NYSE:KOS
|
$1.45 Billion |
|
Telecom Argentina SA ADR
NYSE:TEO
|
$1.45 Billion |
|
Yinson Holdings Bhd
KLSE:7293
|
$1.45 Billion |
|
Zhejiang Huatie Constr Safety
SHG:603300
|
$1.45 Billion |
|
Pci-Suntek Technology Co Ltd
SHG:600728
|
$1.45 Billion |
|
TGS ASA SP.ADR/1
F:TGC0
|
$1.45 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vijaya Diagnostic Centre Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 7,957,140,000 to 9,571,518,000, a change of 1,614,378,000 (20.3%).
- Net income of 1,729,766,000 contributed positively to equity growth.
- Dividend payments of 205,435,000 reduced retained earnings.
- New share issuances of 31,989,000 increased equity.
- Other comprehensive income decreased equity by 101,353,000.
- Other factors increased equity by 159,411,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs1.73 Billion | +18.07% |
| Dividends Paid | Rs205.44 Million | -2.15% |
| Share Issuances | Rs31.99 Million | +0.33% |
| Other Comprehensive Income | Rs-101.35 Million | -1.06% |
| Other Changes | Rs159.41 Million | +1.67% |
| Total Change | Rs- | 20.29% |
Book Value vs Market Value Analysis
This analysis compares Vijaya Diagnostic Centre Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 64.15x to 14.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-03-31 | Rs20.35 | Rs1305.60 | x |
| 2020-03-31 | Rs26.91 | Rs1305.60 | x |
| 2021-03-31 | Rs35.20 | Rs1305.60 | x |
| 2022-03-31 | Rs45.65 | Rs1305.60 | x |
| 2023-03-31 | Rs53.15 | Rs1305.60 | x |
| 2024-03-31 | Rs64.11 | Rs1305.60 | x |
| 2025-03-31 | Rs77.42 | Rs1305.60 | x |
| 2026-03-31 | Rs92.91 | Rs1305.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vijaya Diagnostic Centre Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 21.24%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.57x
- Recent ROE (18.07%) is below the historical average (20.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 22.12% | 15.69% | 0.72x | 1.96x | Rs251.36 Million |
| 2020 | 22.78% | 18.47% | 0.70x | 1.76x | Rs350.84 Million |
| 2021 | 23.53% | 22.44% | 0.70x | 1.51x | Rs485.78 Million |
| 2022 | 23.43% | 23.73% | 0.65x | 1.52x | Rs628.59 Million |
| 2023 | 15.54% | 18.44% | 0.54x | 1.57x | Rs301.59 Million |
| 2024 | 18.08% | 21.70% | 0.56x | 1.50x | Rs531.06 Million |
| 2025 | 17.98% | 21.01% | 0.53x | 1.60x | Rs635.04 Million |
| 2026 | 18.07% | 21.24% | 0.54x | 1.57x | Rs772.61 Million |
Industry Comparison
This section compares Vijaya Diagnostic Centre Limited's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $11,027,349,500
- Average return on equity (ROE) among peers: 18.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vijaya Diagnostic Centre Limited (VIJAYA) | Rs9.57 Billion | 22.12% | 0.57x | $1.45 Billion |
| Krsnaa Diagnostics Limited (KRSNAA) | $8.10 Billion | 7.02% | 0.45x | $187.21 Million |
| Dr. Lal Path Labs Ltd. (LALPATHLAB) | $17.00 Billion | 14.05% | 0.40x | $3.00 Billion |
| Metropolis Healthcare Limited (METROPOLIS) | $5.25 Billion | 24.25% | 0.43x | $304.09 Million |
| Syngene International Limited (SYNGENE) | $28.21 Billion | 14.35% | 0.73x | $1.91 Billion |
| Thyrocare Technologies Limited (THYROCARE) | $5.27 Billion | 33.45% | 0.15x | $919.85 Million |
| Vimta Labs Limited (VIMTALABS) | $2.34 Billion | 17.66% | 0.31x | $273.75 Million |
About Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, and MRI-3T ser… Read more